

## Vision Statement

VentriPoint creates diagnostic tools to monitor patients with heart disease — the number one cause of death in developed countries. Using data received from existing medical imaging devices (e.g. 2D ultrasound), the VentriPoint Medical System generates accurate heart measurements and a three-dimensional model in a rapid and inexpensive manner for a market potential in excess of \$10 Billion.

## Company Overview


VentriPoint Diagnostics Ltd., a publicly traded company with operations based in Seattle, is the result of a 2007 merger between VentriPoint, Inc. and Luca Capital Inc. VentriPoint's solution produces critical heart information by processing standard information received from existing medical imaging equipment (e.g. 2D ultrasound) with its patented and proprietary methods incorporating algorithms and the VentriPoint Knowledge Base. The VentriPoint Medical System ("the VMS") allows medical professionals to economically and accurately create three-dimensional models that provide important shape and volume measurements of a patient's right and left ventricles in only minutes more than the time needed for a routine echocardiogram. VentriPoint delivers these critical measurements and 3-D model via a Web-based service to the users in a matter of seconds.

## Right Ventricle Measurement in Heart Disease

The importance of understanding the shape, volume and function of the right ventricle of the heart has been increasingly described in peer-reviewed medical journals such as the *Circulation*, the Journal of the American Heart Association. Adequate right ventricle function is necessary for normal cardiac hemodynamics. Accurate, reproducible and easily accessible methods to measure right ventricular volume and function are important because it is fundamental and key in evaluating patients to determine the severity of their disease progress, assess the effectiveness of treatment, gauge prognosis and decide the timing of surgical intervention. The majority of congenital heart anomalies primarily affect the right ventricle, and proper patient management is dependent on monitoring right ventricular volume and function. This requires accurate measurements. Monitoring is essential as the right ventricle remodels over time in response to volume and pressure overload and is affected by underlying congenital malformations.

## Knowledge Based Reconstruction with the VMS

Users of the VMS identify key anatomical points on standard images generated by their existing two- or three-dimensional imaging equipment devices. In a matter of seconds, using only these points, Knowledge Based Reconstruction (KBR) produces a three-dimensional model of the right and left ventricles while simultaneously computing highly accurate volume and ejection fractions. KBR employs the knowledge embodied in a database of ventricle shapes and their variations with human disease as developed from a diverse population of patients.



## Corporate Snapshot

### Headquarters

Seattle, Washington

### Business Commenced

January 2005

### Stock Exchange

TSX Venture Exchange

### Stock Symbol

VPT

## Executive Team

### George Adams

President & Chief Executive Officer

### Amol Karnick

Vice President, Sales and Business Development

### Edward Garth

Vice President, Chief Financial Officer

### Scott Ashley

Vice President, Research and Development

### Mary-Pierre Waiss

Vice President, Clinical Development

### Florence H. Sheehan, M.D.

Co- Founder, Chief Scientist

## Board of Directors

### George Adams

CEO, VentriPoint Diagnostics

### Treuman P. Katz

President Emeritus, Seattle Children's Hospital & Regional Medical Center

### Danny Dalla-Longa


Co-founder, i3 Capital Partners

### Brad Harlow

Managing Partner, B. Harlow & Associates, LLC

## VentriPoint Medical System- The first cost-effective and accurate diagnostic tool for measuring right ventricle heart volume and function

The VentriPoint Medical System consists of a computer system, a tracking system with sensor and transmitter, and patented and proprietary methods and software. The anatomical points on the images identified by the user are processed by software and securely sent via the internet to VentriPoint's server. Using Knowledge Based Reconstruction, a three dimensional model is created and volume and ejection fraction measurements are calculated and returned to the users in a matter of seconds compared to the hours necessary to complete tracing with current technology.



## Competitive Landscape

Traditional ultrasound, while inexpensive and easily accessible, does not provide adequate information to accurately evaluate the right ventricle of the heart. MRI and three-dimensional ultrasound provide information from which measurements can be made, but are expensive, not easily accessible in most hospitals, require completing the measurements which can be excessively time consuming and 3D ultrasound can miss up to 25-30% of the right ventricle to measure.

The VMS does not require the customer to purchase additional imaging equipment, as it utilizes images obtained from devices already in use, e.g. widely deployed 2D ultrasounds. This makes it economical for hospitals and clinics alike. The VMS rapidly provides three-dimensional models and highly accurate critical measurements for a fraction of the cost and time of MRI or three-dimensional ultrasound methods.

## VMS Market Applications and Regulatory

Monitoring congenital heart disease in pediatric and adult patients is the initial application for the VentriPoint Medical System, with pulmonary hypertension anticipated in 2010 and other heart disease markets in 2011. VentriPoint has been granted a medical device license for its VentriPoint Medical System from Health Canada and has received European approval to CE Mark its VMS. The first commercial VMS has been installed at the Hospital for Sick Children, 2<sup>nd</sup> largest pediatric research hospital in the world. To complete their review of the Company's 510(k) submission, the U.S. Federal Drug Administration has requested additional information, which has been produced with the support of the Hospital for Sick Children. VentriPoint completed and timely submitted such additional requested information to the FDA and is awaiting the FDA's response.

Market Application	Western/Developed Scans/Year	VentriPoint Scan (US millions)
Congenital Heart Disease	2,520,000	\$ 160
Pulmonary Hypertension	15,000,000	980
Heart Failure (hospital)	5,040,000	320
Coronary Artery Disease (hospital)	4,200,000	265
<b>Subtotal</b>	<b>26,760,000</b>	<b>\$ 1,740</b>
<b>Estimated Private Lab Market HF &amp; CAD- Western/Developed</b>		<b>\$ 5,000</b>
<b>Total Western/Developed Hospital &amp; Est. Private Lab Market</b>		<b>\$ 6,740</b>
<b>Estimated Asian Hospital and Private Lab Market Potential</b>		<b>\$ 6,740</b>
<b>Total World Wide Hospital and Private Lab Market</b>		<b>\$ 13,480</b>

## Scientific Advisory Chair

**Thomas K. Jones, M.D.**

Professor, Seattle Children's Hospital and Regional Medical Center

## Collaborating Institutions

University of Washington

Children's Hospital and Regional

Medical Center, Seattle Washington

Oregon Health & Science University

University Children's Hospital, Switzerland

Royal Brompton & Harefield NHS Trust,

United Kingdom

University of Pennsylvania

Sophia Kinderziekenhuis, The Netherlands

Nationwide Children's Hospital, Columbus Ohio

## General Contact

VentriPoint, Inc.

100 West Harrison Street

Suite 410

Seattle WA 98109

Telephone: (206) 283-0221

Fax: (206) 283-2309

email: [egarth@ventripoint.com](mailto:egarth@ventripoint.com)

[www.ventripoint.com](http://www.ventripoint.com)

## Investor Relations

The Howard Group Inc.

Peter Weichler, Director

Telephone: (403) 221-0915

Fax: (403) 237-8387

Email: [peter@howardgroupinc.com](mailto:peter@howardgroupinc.com)

[www.info@howardgroupinc.com](http://www.info@howardgroupinc.com)